Abstract-The active anaphylactic bronchoconstriction of rats mediated by IgE-like antibody against DNP-Ascaris was inhibited by intravenous and intratracheal treat ment with Y-12,141 in a dose-dependent manner. In both routes, the inhibitory effect of Y-12,141 on this response was more potent than that of disodium cromoglycate (DSCG). The oral administration of Y-12,141 also produced a similar inhibition of the response. The passive anaphylactic bronchoconstriction of guinea pigs mediated by IgG-like antibody against egg albumin was also prevented dose-dependently by treatment with Y-12,141 given intravenously, but not with DSCG. The present results suggest that Y-12,141 may be effective for the treatment of allergic bronchial asthma.In a previous paper (1), we demonstrated that 9-chloro-5-oxo-7-(1H-tetrazol-5-yl) The active anaphylactic bronchoconstriction in rats sensitized with several antigens such as egg albumin provides a model which is similar to human bronchial asthma im munologically and in the response to DSCG (2-6). In addition, the anaphylactic broncho constriction in guinea pigs is usually chosen for the experimental simulation of human allergic bronchial asthma (7). However, the anaphylactic bronchoconstriction in guinea pigs differs from human allergic asthma both in the immunoglobulins involved (8, 9) and in the response to DSCG (10). The present studies were designed to elucidate the effectiveness of Y-12,141 for prophylaxis in the bronchial anaphylaxis in both rats and guinea pigs.
MATERIALS AND METHODS
Animals:Rats, guinea pigs and rabbits were used. The animals were housed under ordinary conditions and allowed free access to food and water.